Peripheral Interventions Market Size, Share, and Trends 2024 to 2033

Peripheral Interventions Market Size and Growth

The global peripheral interventions market size was USD 9.51 billion in 2023, calculated at USD 10.37 billion in 2024 and is expected to reach around USD 22.57 billion by 2033. The market is expanding at a solid CAGR of 9.03% over the forecast period 2024 to 2033. The peripheral interventions market is driven by the elderly population proliferating, and peripheral vascular disorders are rising in parallel.

Peripheral Interventions Market Key Takeaways

• The North America peripheral interventions market size is exhibited at USD 3.42 billion in 2023 and is expected to attain around USD 8.24 billion by 2033, poised to grow at a CAGR of 9.19% between 2024 and 2033.
• North America dominated the market with the largest revenue share of 36% in 2023.
• Asia- Pacific is the fastest growing in the peripheral interventions market during the forecast period.
• By type, the catheters segment dominated the market in 2023.
• By type, the stents segment shows a notable growth in the peripheral interventions market during the forecast period.
• By application, the peripheral artery disease segment dominated the market in 2023.
• By application, the venous thromboembolism segment is the fastest growing in the peripheral interventions market during the forecast period.
• By end- user, the hospitals segment dominated the peripheral interventions market.
• By end- user, the ambulatory surgical centers segment shows a significant growth in the peripheral interventions market during the forecast period.

U.S. Peripheral Interventions Market Size and Growth 2024 to 2033

The U.S. peripheral interventions market size surpassed USD 2.40 billion in 2023 and is projected to attain around USD 5.81 billion by 2033, poised to grow at a CAGR of 9.24% from 2024 to 2033.

North America had dominated in the peripheral interventions market in 2023. North America has an abundance of cutting-edge hospitals and specialty clinics, especially in the U.S. and Canada. These facilities have highly qualified medical staff who can perform intricate peripheral operations and use cutting-edge medical equipment. Medical device regulations are overseen by Health Canada and the U.S. Food and Drug Administration (FDA). These authorities streamline the approval process for new devices, which offer precise standards and procedures. This facilitates the introduction of cutting-edge peripheral intervention technologies to the market.

Due to the high frequency of peripheral vascular illnesses in North America, which are fueled by risk factors like obesity, diabetes, and an aging population, there is a significant demand for cutting-edge medical therapies.

• In March 2023, The US market debut of Shockwave Medical's intravascular lithotripsy catheter for calcified peripheral artery lesions was announced.

Asia-Pacific is the fastest growing in the peripheral interventions market during the forecast period. One major contributing factor is the increasing prevalence of cardiovascular illnesses, especially PAD. The rising incidence of these disorders is attributed to several factors, including aging populations, bad diets, sedentary lifestyles, and smoking. The need for peripheral interventions is rising as a result. These treatments are becoming safer and more successful thanks to developments in medical technology, which include the creation of new and improved instruments for peripheral interventions. Advances in imaging technologies, bioresorbable stents, and drug-coated balloons are among the innovations improving peripheral therapies' results.

Market Overview

Medical equipment, treatments, and processes for identifying and managing illnesses and ailments impacting the peripheral vascular system are all included in the peripheral interventions market. All blood vessels, including the arteries and veins in the arms, legs, and organs that are not part of the heart or brain, are included in this system. Deep vein thrombosis (DVT), varicose veins, and peripheral artery disease (PAD) are common disorders treated via peripheral procedures. Stents, angioplasty balloons, atherectomy, thrombectomy, and embolic protection devices are among the goods and services offered in this industry. Peripheral vascular disorders are on the rise due to an aging population and rising rates of risk factors like diabetes, obesity, and smoking. This fuels the need for efficient intervention technologies and processes. By averting serious problems and decreasing the need for more intrusive treatments, peripheral therapies can make treatment more affordable overall and sustainable.

Peripheral Interventions Market Data and Statistics

• According to reports, venous thromboembolism (VTE) kills 300,000 people and causes 900,000 new cases each year in the United States alone.
• In March 2023, after receiving approval from the US Food and Drug Administration (FDA), Shockwave Medical, Inc., a leader in the development of Intravascular Lithotripsy (IVL) for the treatment of severely calcified cardiovascular disease, announced the device's full commercial availability in the US.

Peripheral Interventions Market Growth Factors

• Globally, the prevalence of PAD is rising due to an aging population and bad lifestyle choices like smoking, diabetes, and obesity. This increases the need for less intrusive methods of treating PAD.
• The need for therapies for age-related illnesses like PAD is predicted to increase dramatically as the world's population ages.
• Peripheral interventions appeal to patients and healthcare providers because they are less expensive, require shorter hospital stays, and have quicker recovery times than standard procedures.
• Growth in the market is driven by the development of new and improved devices, like stents and catheters, leading to more effective and efficient operations.
• Peripheral interventions are more readily available to patients thanks to government programs and insurance reimbursement.

Peripheral Interventions Market Scope

Peripheral Interventions Market Dynamics

Driver

Growing prevalence of chronic ailments

Peripheral consequences from chronic illnesses frequently arise and call for medical attention. For example, to restore blood flow in damaged arteries, procedures such as angioplasty, stenting, atherectomy, and peripheral bypass surgery are required for PAD, a prevalent symptom of atherosclerosis. In a similar vein, peripheral neuropathy and peripheral vascular disease are common in diabetic patients and may call for specific care. More early identification and diagnosis of chronic illnesses have resulted from increased access to healthcare services in various areas. As a result, there is a greater need for prompt therapies to stop the advancement of the disease and lessen its consequences. This increased knowledge and ease of access to healthcare are driving the market for peripheral interventions to grow. This drives the growth of the peripheral interventions market.

Restraint

Lack of awareness regarding peripheral artery disease

The lack of knowledge regarding PAD directly impacts the demand for peripheral interventions. If the disease and its effects are not sufficiently recognized, there will be less patient demand for interventions and less incentive for healthcare systems and providers to invest in the infrastructure and resources required to enable comprehensive PAD management. Considering this, the market for peripheral therapies might expand and innovate more slowly than other branches of cardiovascular therapy. This limits the growth of the peripheral interventions market.

Opportunity

Technological advancements in peripheral intervention devices

Vascular architecture can be seen in detail due to developments in imaging technologies like optical coherence tomography (OCT) and intravascular ultrasonography (IVUS). These technologies lower procedural risks and enhance results by enabling more accurate device placement and navigation. To prevent restenosis, therapeutic drugs are released by drug-eluting stents and balloons, which has greatly increased the long-term success rates of peripheral procedures. Using biodegradable stents reduces the possibility of long-term issues related to permanent implantation because they eventually dissolve after providing structural support. This opens an opportunity for the growth of the peripheral interventions market.

Type Insights

The catheters segment dominated in the peripheral interventions market in 2023. Catheter material innovations, like hydrophilic coatings and biocompatible polymers, lessen the risk of problems, improve mobility, and reduce friction. Real-time visualization and accurate placement are made possible by incorporating imaging technologies like optical coherence tomography (OCT) and intravascular ultrasonography (IVUS) into catheter design. By releasing medication at the intervention site, these catheters lower the likelihood of restenosis and enhance patient outcomes.

The stents segment shows a notable growth in the peripheral interventions market during the forecast period. Considering drug-eluting stents to bare-metal stents, the former dramatically improves long-term outcomes by releasing medication that helps prevent restenosis (re-narrowing of the artery). Modern DES has more flexible designs and smaller struts, which provide better delivery to the target spot and more accessible travel through intricate artery structures. Self-expanding stents can adjust to the changing peripheral artery environment, offering reliable support even in highly mobile regions such as the ankle or knee.

• In August 2022, With the recent CE Mark certification, Medtronic announced the availability of their newest drug-eluting coronary stent, the Onyx Frontier drug-eluting stent (DES). In addition to improving the Resolute Onyx drug-eluting stent's acute performance and clinical data, the Onyx Frontier DES features a novel delivery mechanism. With an improved delivery mechanism intended to boost acute performance in the most challenging instances and improve deliverability, the DES uses the same best-in-class stent platform as Resolute Onyx DES.

Application Insights

The peripheral artery disease segment dominated in the peripheral interventions market in 2023. Due to the high expenses of consequences such critical limb ischemia, amputations, and concomitant hospitalizations, untreated PAD has a significant financial impact. To lower the long-term expenses of managing PADs, governments and healthcare institutions are investing in early intervention techniques and preventive measures.

The diagnosis and treatment of PAD have improved thanks to the development of cutting-edge medical technologies and gadgets. Treatment outcomes have improved due to innovations such as minimally invasive angioplasty procedures, drug-eluting stents, and atherectomy devices. Introducing drug-coated balloons and bioresorbable stents has created new opportunities for efficient PAD therapy, improving patient compliance and lowering restenosis rates.

• In March 2024, according to BD (Becton, Dickinson, and Company), a prominent worldwide provider of medical technology, an investigational device exemption (IDE) study called "AGILITY" which will evaluate the safety and efficacy of the BD Vascular Covered Stent for the treatment of peripheral arterial disease (PAD), has enrolled its first patient.

The venous thromboembolism segment is the fastest growing in the peripheral interventions market during the forecast period. Venous thromboembolism (VTE) is a dangerous illness that starts as a blood clot in a vein, usually in the lower leg, and travels to the lungs, where it causes a pulmonary embolism that can be fatal. After heart attacks and strokes, VTE is the third most prevalent vascular diagnosis in America, affecting between 300,000 and 600,000 people annually. Worldwide, the frequency of VTE, which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is rising. Ageing populations, sedentary lifestyles, and increased rates of obesity and chronic illnesses are all blamed for this increase.

Ultrasound, MRI, and CT scans are examples of advanced imaging technologies that have increased the precision and speed of VTE diagnosis. An accurate and timely diagnosis is essential for managing and treating conditions effectively. There is a positive correlation between higher rates of self-reporting and proactive healthcare-seeking behavior and increased patient education regarding VTE risks, symptoms, and treatments.

End-user Insights

The hospitals segment dominated in the peripheral interventions market in 2023. Modern imaging technologies, including CT, MRI, and angiography scanners, are available in hospitals. These technologies are crucial for precise diagnosis and guiding during peripheral procedures. Intensive care units (ICUs) and post-anesthesia care units (PACUs) provide critical postoperative monitoring and treatment. Reimbursement policies for hospital procedures are generally better in government health programs and insurance plans than in outpatient settings. Patient outcomes are improved by applying strict safety regulations and infection control measures.

The ambulatory surgical centers segment shows a significant growth in the peripheral interventions market during the forecast period. Ambulatory surgical centers (ASCs) are renowned for being more affordable than conventional hospital settings. Due to decreased overhead and operating costs, procedures carried out in ASCs usually have lower total costs. ASCs are more appealing for patients and payers due to their cost advantage, encouraging more peripheral intervention procedures in these settings. Peripheral therapies are in high demand due to an aging population and rising rates of chronic illnesses, including peripheral arterial disease (PAD). ASCs can effectively manage these illnesses by providing specialized treatment, making them well-positioned to serve this expanding patient group.

Peripheral Interventions Market Companies

• Biotronik SE & Co. KG
• Teleflex Incorporated
• Abbott Laboratories
• Boston Scientific Corporation
• Cook Medical
• W. L. Gore & Associates Inc
• Cardinal Health Inc
• Angio Dynamics Inc
• Medtronic
• B. Braun Melsungen AG
• Terumo Corporation
• Becton Dickinson and Company

Recent Developments

• In February 2024, the next-generation intermediate catheter with TruCourse, CEREGLIDE 71 Intermediate Catheter, has been launched by CERENOVUS, Inc., a Johnson & Johnson MedTech division. It is intended for the revascularization of individuals experiencing acute ischemic stroke.
• In June 2023, Blue Medical Devices, a Wellinq group company headquartered in Helmond, the Netherlands, has been acquired by Translumina, a leader in the global market for interventional cardiovascular medical devices with manufacturing facilities in Germany and India. The company was founded in 2013 and manufactures a cutting-edge assortment of balloon catheters, such as Drug-Coated Balloons (DCB) and other specialty balloons for intricate cardiac procedures.

Segments Covered in the Report

By Product

• Catheters
• Sheath
• Stents
• Bare Metal Stents
• Drug-eluting Stents
• Guide Wires
• Atherectomy Devices
• Embolic Devices
• IVC Filters

By Application

• Peripheral Artery Disease
• Venous Thromboembolism
• Others

By End-use

• Hospitals
• Catheterization Laboratories
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa